SierraSil Joint Formula 14 as an Ergogenic Aid to Performance in Athletes

Not Applicable

Completed

• Conditions: Muscle Fatigue; Muscle Power
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: SierraSil

• Registration Number: NCT01932281
• Lead Sponsor: University of British Columbia

Brief Summary

The purpose of this study is to examine whether supplementation with SierraSil can improve anaerobic power and reduce muscle fatigue in a group of well-trained athletes.

A secondary purpose is to examine the effect of SierraSil on the severity of delayed onset muscle soreness.

Detailed Description

This is a double blind, crossover, pilot study that will examine the effect of SierraSil supplementation on the determinants of human performance. Anaerobic capacity, muscle fatigue, the severity of delayed onset muscle soreness (DOMS) and markers of inflammation will be measured before and after 3 weeks of supplementation with SierraSil or placebo. There will be a 3 week washout period prior to the crossover to ensure SierraSil supplementation has no residual effect.

Study Timeline

• Study First Submitted: 2013-08-27
• Study First Submitted QC: 2013-08-29
• Study First Posted: 2013-08-30
• Study Start: 2014-05
• Primary Completion: 2014-09
• Study Completion: 2014-09
• Status Verified: 2015-07
• Last Update Submitted: 2015-07-13
• Last Update Posted: 2015-07-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 10

Inclusion Criteria

• no contraindications to strenuous exercise

Read More

Exclusion Criteria

• muscle or joint injury
• taking any form of anti-inflammatory or pain medication
• females due to the variability that might be introduced due to the phases of the menstrual cycle

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
SierraSil	SierraSil	SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.

Primary Outcome Measures

Name	Time	Method
change in total anaerobic capacity	change from baseline at 3 weeks

Trial Locations

Locations (1)

University of British Columbia; 🇨🇦 Vancouver, British Columbia, Canada